Jason Broderick

4 weeks ago | targetedonc.com | Jason Broderick

A small, single-center Italian study showed positive signals of efficacy and safety for melphalan flufenamide (melflufen) use in combination with dexamethasone in a real-world setting for patients with relapsed/refractory multiple myeloma,according to findings shared at the 6th European Myeloma Network Meeting in Athens, Greece.1,2 Melflufen is approved in Europe under the trade name Pepaxti for use in this setting; however, in the United States, the FDA withdrew its approval for melflufen...

1 month ago | targetedonc.com | Jason Broderick

The dual-immunotherapy combination of nivolumab (Opdivo) and ipilimumab (Yervoy) showed a strong clinical benefit at 12 months with a trend toward prolongation of overall survival (OS) vs standard of care (SOC) in patients with advanced or metastatic non-clear cell renal cell carcinoma (nccRCC), according to findings from the phase 2 SUNNIFORECAST study published in the Annals of Oncology.1 At a median follow-up of 21.5 months (range, 0.0 -70.2), the median OS was 33.2 months with...

1 month ago | targetedonc.com | Jason Broderick

Among patients with HPV-negative locoregionally advanced head and neck squamous cell carcinoma (HNSCC), neoadjuvant nivolumab (Opdivo) plus chemotherapy with subsequent response-adapted de-escalated chemoradiation therapy (CRT) elicited promising efficacy with reduced acute toxicity occurring in deep responders.1,2 These results, which come from the phase 2 DEPEND trial (NCT03944915),1 showed that at a median follow-up of 20 months (range, 13-40), 53% (95% CI, 35%-70%) of patients reached a...

1 month ago | targetedonc.com | Jason Broderick

Pivotal data showing strong clinical activity for taletrectinib in patients with ROS1 fusion–positive non–small cell lung cancer (NSCLC) were published in the Journal of Clinical Oncology, with the FDA currently reviewing a new drug application (NDA) for use of the ROS1 tyrosine kinase inhibitor (TKI) in this setting.1,2The data are from a pooled analysis of the single-arm, open-label, multicenter phase 2 TRUST-I and TRUST-II trials.

1 month ago | targetedonc.com | Jason Broderick

the risk of disease progression or death vs fulvestrant in patients with estrogen receptor 1-mutant (ESR1m),estrogen receptor–positive/HER2– advanced or metastatic breast cancer with disease progression after treatment with CDK 4/6 inhibitors and endocrine therapy, according to topline results from the phase 3 VERITAC-2 clinical trial (NCT05654623).1 In the ESR1m subgroup, vepdegestrant met part of the primary study end point by significantly improving progression-free survival (PFS) vs...